Skip to main content
Equibles
VKTX logo

VKTX · Viking Therapeutics, Inc.

Track VKTX — free

Use VKTX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research VKTX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$29.22 +1.64 (+5.95%) At close · Nov 13
Russell 1000 member Rebalance outlook locked
Market Cap
$3.73B
Shares
127.52M
Volume · Nov 13 8.87M Avg daily vol (3M) 5.11M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$29.22 Open$27.44 Day$26.69–29.96 52W close$24.21–42.13 Avg vol 30d4.8M Short int24.2M · 18.9% of shares · 5.4d Short vol60% Last earningsOct 28, 2026 DataJan 2020–Nov 2026 Filing10-Q · Oct 29

Up next

Next earnings call
Feb 10, 2027 Est · unconfirmed · in 12 wks
Q3 2026 earnings call transcript
call held Oct 28, 2026
Play latest call

Latest documents

2026
Oct 29
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Quarterly report for FY2026 Q3

Viking Therapeutics incurred $432.7 million in research and development expenses for the nine months ended September 30, 2026. It reported $960.0 million in cash and investments, which it believes will fund operations through at least December 31, 2027.

Revenue $0 Net loss $183.19M Diluted EPS -$1.55
Read from the MD&A section
Oct 28
Earnings call
Q3 2026 earnings call

Viking Therapeutics said both VANQUISH Phase III studies were fully enrolled, initiated the oral SUNRISE Phase III program, reported positive maintenance-dosing results, and ended the third quarter with $960 million in cash after offerings raising gross proceeds of approximately $575 million.

Oct 28
Current report 8-K
Financial results

Viking Therapeutics reported a $183.2 million third-quarter net loss and $960 million in cash, while advancing VANQUISH and SUNRISE Phase 3 trials of VK2735, reporting positive maintenance-study results and initiating Part 2.

Sep 28
Current report 8-K Events of Sep 23
Entered into a material agreement, New debt or off-balance-sheet obligation

Viking Therapeutics sold 7,857,143 shares at $35.00 per share plus 1,178,571 additional shares, generating approximately $297.0 million net. It issued $225,000,000 plus $33,750,000 of 2.00% Convertible Senior Notes due 2032, generating approximately $250.8 million net.

Read from the first part of this long document
Sep 22
Current report 8-K
Other events

Viking Therapeutics announced VK2735 maintenance-study results showing 22% placebo-adjusted weight loss at Week 33 with weekly 17.5 mg dosing, up to 97% maintenance with every-other-week dosing and 90% with monthly dosing, and GI adverse-event rates similar to placebo.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$627.20M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$426.95M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+5.1%
Year over year · more shares
Price change (1Y)
-25.1%
Trailing year
Short interest
18.9%
Latest settlement · 5.4 days to cover
View all 125 metrics

Mentioned in fund letters

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Weak Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −9%
below
Price vs 50-day avg −0%
below
RSI (14) 55
neutral
MACD trend Positive
52-week position 28%
mid-range
Momentum
relative strength
Weak
1-month return +16%
trailing
6-month return −5%
trailing
YTD return −17%
this year
Relative strength −6%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $29 › 200d $32 — 200d above 50d
Institutional flow Accumulating
373 of 444 funds reported for Sep 30 · net +5.3M sh shares · +49 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
18.95% of shares out · ▼ -5.4% MoM · 5.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
444 holders — near 3-yr high, broad support
Squeeze score 74
high risk · 0–100
Fundamentals
Strong
EPS growth −216%
Y/Y
Buyback $750.0M
authorized
Balance sheet $165.8M
net cash
Quant / Vol
risk profile
Very High
Volatility 69%
annualized · 1-yr
Max drawdown −43%
past year
ATR 6.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Jul 28, 2021
OpEx guidance · back half of the year 50% – 70%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−9% Bearish
Price vs 50-day avg
−0% Neutral
RSI (14)
55 Neutral
MACD trend
Positive Bullish
52-week position
28% Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $29 › 200d $32 — 200d above 50d
Institutional flow Accumulating
373 of 444 funds reported for Sep 30 · net +5.3M sh shares · +49 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
18.95% of shares out · ▼ -5.4% MoM · 5.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
444 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $24 Now $29 · 28% Range high $42
vs 200-day avg -9% vs 50-day avg 0%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
VKTX
Viking Therapeutics, Inc.
this stock
$3.73B -16.9% — — 18.9%
VRTX
Vertex Pharmaceuticals Inc
 $136.56B +18.8% +46.2% 34.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $98.84B +23.8% +20.8% 21.1 2.1%
MRNA
Moderna, Inc.
 $90.38B +657.4% +4.3% — 8.2%
CSLLY
Csl Ltd
 $66.05B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
448
% held
71.8%
Reported
373 of 444
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
278
View
Short & Settlement
Short Interest Falling
Shares short
24.2M
Days to cover
5.4d
Change
-1.4M sh
View
Short Volume
Short vol %
60%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
34.9K
Value
$929.5K
As of
Oct 14, 2026
View
Off-Exchange
Off-exchange %
50.6%
Week of
Oct 5, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-359.6M
EPS diluted
$-3.19
View
Buybacks
Authorized · 2 programs
$750.0M
View
Filings
SEC Filings
Latest
10-Q
Filed
Oct 29, 2026
This year
15

Viking Therapeutics incurred $432.7 million in research and development expenses for the nine months ended September 30, 2026. It reported $960.0 million in cash and investments, which it believes will fund operations through at least December 31, 2027.

View
Proposed Sales
Value
$609.6K
Shares
18.2K
Filed
Jul 29, 2026
View
Earnings & Events
Webcasts
Last webcast
Oct 28, 2026
View
Investor Relations
Latest news
Viking Therapeutics Reports Third…
Published
Oct 28, 2026
View

Performance

5D 20D 120D MTD YTD
VKTX +8.9% +16.1% -5.1% +7.1% -16.9%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY +6.3% +17.3% -5.6% +7.3% -27.6%

Capital returns

Buyback programs · 2 active · as of Jul 30, 2026
Authorized (total)
$750.00M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1607678 CUSIP 92686J106 13F (30d) 336 filings 302 filers Visit website Investor relations